Yiling Lu, M.D.

Peer-Reviewed Articles

1. Zhang S, Hong HI, Mak VCY, Zhou Y, Lu Y, Zhuang G, Cheung LWT. Vertical inhibition of p110alpha/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. Mol Oncol 19(4):1132-1154, 2025. e-Pub 2025. PMID: 39543937.
2. Liu W, Li J, Tang Y, Zhao Y, Liu C, Song M, Ju Z, Kumar SV, Lu Y, Akbani R, Mills GB, Liang H. DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis. Nat Commun 16(1):2256, 2025. e-Pub 2025. PMID: 40050282.
3. Lipchick B, Guterres AN, Chen HY, Zundell DM, Del Aguila S, Reyes-Uribe PI, Tirado Y, Basu S, Yin X, Kossenkov AV, Lu Y, Mills GB, Liu Q, Goldman AR, Murphy ME, Speicher DW, Villanueva J. Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistant NRAS-mutant melanoma. Sci Transl Med 17(784):eadp8913, 2025. e-Pub 2025. PMID: 39908352.
4. Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak DR, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E 3rd, Liotta LA, Mills GB, Nishizuka SS. Targeted dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit. Mol Cell Proteomics:100870, 2024. e-Pub 2024. PMID: 39461475.
5. Li J, Liu W, Mojumdar K, Kim H, Zhou Z, Ju Z, Kumar SV, Ng PK, Chen H, Davies MA, Lu Y, Akbani R, Mills GB, Liang H. A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies. Nat Cancer 5(10):1579-1595, 2024. e-Pub 2024. PMID: 39227745.
6. Wu CC, Huang L, Zhang Z, Ju Z, Song X, Kolb EA, Zhang W, Gill J, Ha M, Smith MA, Houghton P, Morton CL, Kurmasheva R, Maris J, Mosse Y, Lu Y, Gorlick R, Futreal PA, Beird HC. Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models. Sci Rep 14(1):19891, 2024. e-Pub 2024. PMID: 39191826.
7. Li, Y, Dobrolecki, LE, Sallas, C, Zhang, X, Kerr, TD, Bisht, D, Wang, Y, Awasthi, S, Kaundal, B, Wu, S, Peng, W, Mendillo, ML, Lu, Y, Jeter, CR, Peng, G, Liu, J, Westin, SN, Sood, AK, Lewis, MT, Das, J, Yi, S, Bedford, MT, McGrail, DJ, Sahni, N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118413.
8. Lu Y, Tang Q, Pan Q, Zhao L, Zhu Y. A Heuristic-Based Adaptive Iterated Greedy Algorithm for Lot-Streaming Hybrid Flow Shop Scheduling Problem with Consistent and Intermingled Sub-Lots. Sensors (Basel) 23(5), 2023. e-Pub 2023. PMID: 36905012.
9. Lu Y, Lin J, Bian T, Chen J, Liu D, Ma M, Gao Z, Chen J, Ju D, Wang X. Risk control of host cell proteins in one therapeutic antibody produced by concentrated fed-batch (CFB) mode. Eng Life Sci 23(3):e2200060, 2023. e-Pub 2023. PMID: 36874608.
10. Ng ASN, Zhang S, Mak VCY, Zhou Y, Yuen Y, Sharma R, Lu Y, Zhuang G, Zhao W, Pang HH, Cheung LWT. AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance. Cell Rep 41(11):111821, 2022. e-Pub 2022. PMID: 36516775.
11. Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H. Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell 40(11):1324-1340.e8, 2022. e-Pub 2022. PMID: 36332624.
12. Shehwana H, Kumar SV, Melott JM, Rohrdanz MA, Wakefield C, Ju Z, Siwak DR, Lu Y, Broom BM, Weinstein JN, Mills GB, Akbani R. RPPA SPACE: An R package for normalization and quantitation of Reverse-Phase Protein Array (RPPA) data. Bioinformatics 38(22):5131-5133. doi: 10.1093/bioinformatics/btac665, 2022. e-Pub 2022. PMID: 36205581.
13. Fujita M, Chen MM, Siwak DR, Sasagawa S, Oosawa-Tatsuguchi A, Arihiro K, Ono A, Miura R, Maejima K, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Lee JS, Lu Y, Mills GB, Liang H, Nishizuka SS, Nakagawa H. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun 13(1):6481, 2022. e-Pub 2022. PMID: 36309506.
14. Gross SM, Dane MA, Smith RL, Devlin KL, McLean IC, Derrick DS, Mills CE, Subramanian K, London AB, Torre D, Evangelista JE, Clarke DJB, Xie Z, Erdem C, Lyons N, Natoli T, Pessa S, Lu X, Mullahoo J, Li J, Adam M, Wassie B, Liu M, Kilburn DF, Liby TA, Bucher E, Sanchez-Aguila C, Daily K, Omberg L, Wang Y, Jacobson C, Yapp C, Chung M, Vidovic D, Lu Y, Schurer S, Lee A, Pillai A, Subramanian A, Papanastasiou M, Fraenkel E, Feiler HS, Mills GB, Jaffe JD, Ma'ayan A, Birtwistle MR, Sorger PK, Korkola JE, Gray JW, Heiser LM. A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses. Commun Biol 5(1):1066, 2022. e-Pub 2022. PMID: 36207580.
15. Yan G, Luna A, Wang H, Bozorgui B, Li X, Sanchez M, Dereli Z, Kahraman N, Kara G, Chen X, Zheng C, McGrail D, Sahni N, Lu Y, Babur O, Cokol M, Lim B, Ozpolat B, Sander C, Mills GB, Korkut A. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Rep 40(11):111304, 2022. e-Pub 2022. PMID: 36103824.
16. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res 28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278, 2022. e-Pub 2022. PMID: 35736816.
17. Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Nat Commun 13(1):4000, 2022. e-Pub 2022. PMID: 35810190.
18. Wei S, Yin D, Yu S, Lin X, Savani MR, Du K, Ku Y, Wu D, Li S, Liu H, Tian M, Chen Y, Bowie M, Hariharan S, Waitkus M, Keir ST, Sugarman ET, Deek RA, Labrie M, Khasraw M, Lu Y, Mills GB, Herlyn M, Wu K, Liu L, Wei Z, Flaherty KT, Abdullah K, Zhang G, Ashley DM. Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. Clin Cancer Res 28(10):2180-2195, 2022. e-Pub 2022. PMID: 35247901.
19. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. e-Pub 2022. PMID: 35538088.
20. Li J, Lu H, Ng PK, Pantazi A, Ip CKM, Jeong KJ, Amador B, Tran R, Tsang YH, Yang L, Song X, Dogruluk T, Ren X, Hadjipanayis A, Bristow CA, Lee S, Kucherlapati M, Parfenov M, Tang J, Seth S, Mahadeshwar HS, Mojumdar K, Zeng D, Zhang J, Protopopov A, Seidman JG, Creighton CJ, Lu Y, Sahni N, Shaw KR, Meric-Bernstam F, Futreal A, Chin L, Scott KL, Kucherlapati R, Mills GB, Liang H. A functional genomic approach to actionable gene fusions for precision oncology. Sci Adv 8(6):eabm2382, 2022. e-Pub 2022. PMID: 35138907.
21. Shan Y, Cui J, Kang X, Tang W, Lu Y, Gao Y, Chen L. Aquaporin-8 overexpression is involved in vascular structure and function changes in placentas of gestational diabetes mellitus patients. Open Life Sci 17(1):1473-1486, 2022. e-Pub 2022. PMID: 36448064.
22. Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clin Cancer Res 27(24):6800-6814, 2021. e-Pub 2021. PMID: 34593527.
23. Guo, E, Xiao, R, Wu, Y, Lu, F, Liu, C, Yang, B, Li, X, Fu, Y, Wang, Z, Li, Y, Huang, Y, Li, F, Wu, X, You, L, Qin, T, Lu, Y, Huang, X, Ding, M, Mills, GB, Sun, C, Chen, G. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. Journal of Experimental Medicine 219(1), 2021. e-Pub 2021. PMID: 34825915.
24. Oliveira, Éd, Chauhan, J, Silva, Jd, Carvalho, LC, Dias, D, Carvalho, Dd, Watanabe, LM, Rebecca, VW, Mills, GB, Lu, Y, da Silva, AF, Consolaro, ML, Herlyn, M, Possik, PA, Goding, CR, Maria-Engler, SS. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research 173, 2021. e-Pub 2021. PMID: 34560251.
25. Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, Fukunaga-Kalabis M, Krepler C, Aza-Blanc P, Yang CC, Delvadia B, Tong C, Huang Y, Delvadia M, Morias AS, Sproesser K, Brafford P, Wang JX, Beqiri M, Somasundaram R, Vultur A, Hristova DM, Wu LW, Lu Y, Mills GB, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Amaravadi RK, Kwong LN, Frederick DT, Boland GM, Salvino JM, Speicher DW, Flaherty KT, Ronai ZA, Herlyn M. Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Res 81(20):5230-5241, 2021. e-Pub 2021. PMID: 34462276.
26. Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene 40(37):5590-5599, 2021. e-Pub 2021. PMID: 34304249.
27. Yaegashi M, Iwaya T, Sasaki N, Fujita M, Ju Z, Siwak D, Hachiya T, Sato K, Endo F, Kimura T, Otsuka K, Sugimoto R, Sugai T, Liotta L, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. Br J Cancer 124(9):1556-1565, 2021. e-Pub 2021. PMID: 33658639.
28. Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, Chaluvally-Raghavan P. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Res 80(24):5554-5568, 2020. e-Pub 2020. PMID: 33087324.
29. Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell 38(6):829-843.e4, 2020. e-Pub 2020. PMID: 33157050.
30. Marusak C, Thakur V, Li Y, Freitas JT, Zmina PM, Thakur VS, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, Moll T, Boland GM, Herlyn M, Zhang G, Bedogni B. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clin Cancer Res 26(22):6039-6050, 2020. e-Pub 2020. PMID: 32820016.
31. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Group MW, working group PNSMCM, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, Consortium P. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):6232, 2020. e-Pub 2020. PMID: 33257764.
32. Vinik Y, Ortega FG, Mills GB, Lu Y, Jurkowicz M, Halperin S, Aharoni M, Gutman M, Lev S. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Sci Adv 6(40), 2020. e-Pub 2020. PMID: 33008904.
33. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Group MW, working group PNSMCM, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, Consortium P. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):4748, 2020. e-Pub 2020. PMID: 32958763.
34. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Clinical Translation PTSA, Boutros PC, Consortium P. Sex differences in oncogenic mutational processes. Nat Commun 11(1):4330, 2020. e-Pub 2020. PMID: 32859912.
35. Liang J, Wang L, Wang C, Shen J, Su B, Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, Lu Y, Jain AK, Zhou Z, Liang H, Sun SC, Lu C, Xu ZX, Yu Q, Shao S, Chen X, Gao M, Claret FX, Ding Z, Chen J, Chen P, Barton MC, Peng G, Mills GB, Heimberger AB. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res 8(7):952-965, 2020. e-Pub 2020. PMID: 32265228.
36. Rao L, Mak VCY, Zhou Y, Zhang D, Li X, Fung CCY, Sharma R, Gu C, Lu Y, Tipoe GL, Cheung ANY, Mills GB, Cheung LWT. p85β regulates autophagic degradation of AXL to activate oncogenic signaling. Nat Commun 11(1):2291, 2020. e-Pub 2020. PMID: 32385243.
37. Genomes Consortium IPAOW. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
38. Sun C, Li X, Guo E, Li N, Zhou B, Lu H, Huang J, Xia M, Shan W, Wang B, Li K, Weng D, Xu X, Gao Q, Wang S, Hu J, Lu Y, Mills GB, Chen G. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. Oncogene 39(8):1681-1695, 2020. e-Pub 2020. PMID: 31705064.
39. Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS One 15(10):e0239966, 2020. e-Pub 2020. PMID: 33027286.
40. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep 29(13):4389-4406.e10, 2019. e-Pub 2019. PMID: 31875548.
41. Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest 129(12):5343-5356, 2019. e-Pub 2019. PMID: 31682236.
42. Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P. Identification and validation of a prognostic proteomic signature for cervical cancer. Gynecol Oncol 155(2):324-330, 2019. e-Pub 2019. PMID: 31477280.
43. Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, Gowda R, Robertson GP, Warrick JI, Herlyn M, Imamura Y, Kimball SR, DeGraff DJ, Snyder NW, Aird KM. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Rep 28(8):1971-1980.e8, 2019. e-Pub 2019. PMID: 31433975.
44. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Research Network CGA, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. Immunity 51(2):411-412, 2019. e-Pub 2019. PMID: 31433971.
45. Chen MM, Li J, Wang Y, Akbani R, Lu Y, Mills GB, Liang H. TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. Mol Cell Proteomics 18(8 suppl 1):S15-S25, 2019. e-Pub 2019. PMID: 31201206.
46. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. e-Pub 2019. PMID: 31185210.
47. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 10(37):3533-3546, 2019. e-Pub 2019. PMID: 31191824.
48. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569(7757):503-508, 2019. e-Pub 2019. PMID: 31068700.
49. Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker BL, Yang R, Feltcher C, Peng K, Feng C, Chen H, Lee RX, Kerestes H, Niu J, Kumar S, Xu W, Zhang J, Wei Z, Martin JS, Liu X, Mills G, Lu Y, Guo W, Sun L, Zhang L, Weeraratna A, Herlyn M, Wei W, Lee FS, Xu X. Author Correction: Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 10(1):1211, 2019. e-Pub 2019. PMID: 30858377.
50. Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nat Commun 10(1):716, 2019. e-Pub 2019. PMID: 30755611.
51. Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 565(7738):E4, 2019. e-Pub 2019. PMID: 30532003.
52. Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y, Zhao H. CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1. Front Oncol 9:802, 2019. e-Pub 2019. PMID: 31497537.
53. Fan XJ, Huang Y, Wu PH, Yin XK, Yu XH, Fu XH, Feng LL, Wang YL, Yi HJ, Chen ZT, Yin JX, Zhang DL, Feng WX, Bai SM, Kim T, Mills GB, Lu YL, Wan XB, Wang L. Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking. J Cancer 10(20):4978-4988, 2019. e-Pub 2019. PMID: 31598170.
54. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, [Lu Y] TRN, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
55. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, [Lu Y] CGARN, Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep 25(5):1304-1317.e5, 2018. e-Pub 2018. PMID: 30380420.
56. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, [Lu Y] CGARN, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
57. Hsieh HJ, Zhang W, Lin SH, Yang WH, Wang JZ, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills GB, Peng G. Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9(1):3982, 2018. e-Pub 2018. PMID: 30266942.
58. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718):382-386, 2018. e-Pub 2018. PMID: 30089911.
59. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, [Lu Y] CGARN, Rätsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell 34(2):211-224.e6, 2018. e-Pub 2018. PMID: 30078747.
60. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Network TR, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 174(4):1033, 2018. e-Pub 2018. PMID: 30096301.
61. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, Group MW, [Lu Y] CGARN, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 174(4):1034-1035, 2018. e-Pub 2018. PMID: 30096302.
62. Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z. AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18(1):742, 2018. e-Pub 2018. PMID: 30012111.
63. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM, [Lu Y] CGARN, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23(11):3392-3406, 2018. e-Pub 2018. PMID: 29898407.
64. Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, Carter W, Meredith RK, Krishnamurthy S, Ding Z, Beechem JM, Mills GB. Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Mol Cell Proteomics 17(6):1245-1258, 2018. e-Pub 2018. PMID: 29531020.
65. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, [Lu Y] CGARN, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23(12):3698, 2018. e-Pub 2018. PMID: 29925010.
66. Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10(5), 2018. e-Pub 2018. PMID: 29650805.
67. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9(1):1777, 2018. e-Pub 2018. PMID: 29725014.
68. Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, Zhou Z, Mojumdar K, Jeong KJ, Labrie M, Tsang YH, Zhang M, Lu Y, Hwu P, Scott KL, Liang H, Mills GB. A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell 33(5):817-828.e7, 2018. e-Pub 2018. PMID: 29706454.
69. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G, [Lu Y] CGARN. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173(2):305-320.e10, 2018. e-Pub 2018. PMID: 29625049.
70. Du D, Ma W, Yates MS, Chen T, Lu KH, Lu Y, Weinstein JN, Broaddus RR, Mills GB, Liu Y. Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9(28):19704-19715, 2018. e-Pub 2018. PMID: 29731976.
71. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, [Lu Y] CGARN, Monnat RJ, Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. e-Pub 2018. PMID: 29617664.
72. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, [Lu Y] CGAN, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173(2):291-304.e6, 2018. e-Pub 2018. PMID: 29625048.
73. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwaitkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WT, Robertson AG, [Lu Y] CGARN, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23(1):313-326.e5, 2018. e-Pub 2018. PMID: 29617669.
74. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, [Lu Y] CGARN, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep 23(1):282-296.e4, 2018. e-Pub 2018. PMID: 29617667.
75. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, [Lu Y] CGARN, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. Immunity 48(4):812-830.e14, 2018. e-Pub 2018. PMID: 29628290.
76. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Working Group FA, [Lu Y] CGARN, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep 23(1):227-238.e3, 2018. e-Pub 2018. PMID: 29617662.
77. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, [Lu Y] CGARN, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33(4):706-720.e9, 2018. e-Pub 2018. PMID: 29622465.
78. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, [Lu Y] CGARN, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173(2):400-416.e11, 2018. e-Pub 2018. PMID: 29625055.
79. Chen H, Li C, Peng X, Zhou Z, Weinstein JN, [Lu Y] CGARN, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173(2):386-399.e12, 2018. e-Pub 2018. PMID: 29625054.
80. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN, [Lu Y] CGARN, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep 23(1):255-269.e4, 2018. e-Pub 2018. PMID: 29617665.
81. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, [Lu Y] CGARN, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212.e6, 2018. e-Pub 2018. PMID: 29617660.
82. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, [Lu Y] CGARN, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337.e10, 2018. e-Pub 2018. PMID: 29625050.
83. McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SY, Sahni N. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9(1):1317, 2018. e-Pub 2018. PMID: 29615613.
84. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, [Lu Y] CGARN, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4):676-689.e3, 2018. e-Pub 2018. PMID: 29622463.
85. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, [Lu Y] CGARN, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23(1):181-193.e7, 2018. e-Pub 2018. PMID: 29617659.
86. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, [Lu Y] CGARN, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep 23(1):172-180.e3, 2018. e-Pub 2018. PMID: 29617658.
87. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, Group MW, [Lu Y] CGARN, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173(2):371-385.e18, 2018. e-Pub 2018. PMID: 29625053.
88. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, [Lu Y] CGARN, Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33(4):721-735.e8, 2018. e-Pub 2018. PMID: 29622466.
89. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ, [Lu Y] CGARN, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Rep 23(1):270-281.e3, 2018. e-Pub 2018. PMID: 29617666.
90. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, [Lu Y] CGARN, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173(2):338-354.e15, 2018. e-Pub 2018. PMID: 29625051.
91. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, [Lu Y] CGARN, Piwnica-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep 23(1):213-226.e3, 2018. e-Pub 2018. PMID: 29617661.
92. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L, Group MW, [Lu Y] CGARN. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6(3):271-281.e7, 2018. e-Pub 2018. PMID: 29596782.
93. Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33(3):450-462.e10, 2018. e-Pub 2018. PMID: 29533785.
94. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, [Lu Y] CGAN. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6(3):282-300.e2, 2018. e-Pub 2018. PMID: 29596783.
95. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford PA, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland G, Wei Z, Nathanson KL, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. e-Pub 2018. PMID: 29563139.
96. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. e-Pub 2018. PMID: 29533782.
97. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, [Lu Y] CGAN, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33(2):244-258.e10, 2018. e-Pub 2018. PMID: 29438696.
98. Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget 9(9):8206-8222, 2018. e-Pub 2018. PMID: 29492189.
99. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
100. Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, Liang H. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res 77(21):e51-e54, 2017. e-Pub 2017. PMID: 29092939.
101. address: elizabethdemicco@sinaihealthsystemca CGARN[YE, Research Network CGA. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965.e28, 2017. e-Pub 2017. PMID: 29100075.
102. Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, Levi SM, Wei Z, Barber-Rotenberg JS, Murphy ME, Mills GB, Lu Y, Rabinowitz J, Marmorstein R, Liu Q, Liu S, Xu X, Herlyn M, Zoncu R, Brady DC, Speicher DW, Winkler JD, Amaravadi RK. A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7(11):1266-1283, 2017. e-Pub 2017. PMID: 28899863.
103. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21(7):1953-1967, 2017. e-Pub 2017. PMID: 29141225.
104. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Network TR, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171(3):540-556.e25, 2017. e-Pub 2017. PMID: 28988769.
105. Städler N, Dondelinger F, Hill SM, Akbani R, Lu Y, Mills GB, Mukherjee S. Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. Bioinformatics 33(18):2890-2896, 2017. e-Pub 2017. PMID: 28535188.
106. address: andrew_aguirre@dfciharvardedu CGARN[YE, Research Network CGA. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32(2):185-203.e13, 2017. e-Pub 2017. PMID: 28810144.
107. Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res 27(7):1112-1125, 2017. e-Pub 2017. PMID: 28411194.
108. Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, Mills GB, Gimotty PA, Xu X, Herlyn M, Zhang L. Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77(14):3745-3757, 2017. e-Pub 2017. PMID: 28473531.
109. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, [Lu Y] CGAN, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 19(13):2878-2880, 2017. e-Pub 2017. PMID: 28658632.
110. address: wheeler@bcmedu CGARN[YE, Research Network CGA. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169(7):1327-1341.e23, 2017. e-Pub 2017. PMID: 28622513.
111. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392), 2017. e-Pub 2017. PMID: 28566428.
112. Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv 3(4):e1600957, 2017. e-Pub 2017. PMID: 28439535.
113. Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, Ju Z, Panupinthu N, Yang JY, Gagea MM, Ng PK, Zhang F, Mills GB. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. Cancer Res 77(7):1637-1648, 2017. e-Pub 2017. PMID: 28202507.
114. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, [Lu Y] CGARN, Weinstein JN, Zhang J, Akbani R, Levine DA. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell 31(3):411-423, 2017. e-Pub 2017. PMID: 28292439.
115. [Lu Y] CGARN, of Med AEC, Services AB, Hospital BC, of Medicine BC, of Hope BRIOC, on Aging BIFR, Sciences Centre CMSG, School HM, Health Services HFGCC&IACC, for Biotechnology HI, ILSbio, LLC, of Medicine IUS, Human Virology IO, Systems Biology IF, Consortium IG, Biomedical L, Hospital MG, Washington University MGIA, of Wisconsin MC, South Carolina MUO, Cancer Center MSK, Center MM, NantOmics, Institute NC, Hospital N, Abuja, Nigeria, Research Institute NHG, Health Sciences NIOE, Communication Disorders NIOD&, Bank OT, Sciences Centre LH, Bank OT, Cancer Research OIF, Bank OT, Hospital TO, &Science University OH, Cancer Institute SOC, Center CM, SRA International SRA, Health System SJC, &Harvard University E&LBIOMIOT, Children's Hospital RIAN, Hopkins University SKCCCAJ, Bergen UO, Cancer Center UOTMA, Teaching Hospital UOA, at Birmingham UOA, California UO, Irvine, Santa Cruz UOC, Medical Center UOK, Lausanne UO, Sciences Center UONMH, Chapel Hill UONCA, Oklahoma UO. Integrated genomic and molecular characterization of cervical cancer. Nature 543(7645):378-384, 2017. e-Pub 2017. PMID: 28112728.
116. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, [Lu Y] CGAN, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 18(11):2780-2794, 2017. e-Pub 2017. PMID: 28297679.
117. Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie JM, Gibbons DL, Mills GB, Wistuba II, Creighton CJ. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene 36(10):1384-1393, 2017. e-Pub 2017. PMID: 27775076.
118. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, [Lu Y] CGARN, Pacak K, Nathanson KL, Wilkerson MD. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell 31(2):181-193, 2017. e-Pub 2017. PMID: 28162975.
119. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2017. e-Pub 2017. PMID: 28196595.
120. George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760, 2017. e-Pub 2017. PMID: 28097235.
121. [Lu Y] CGARN, Asan University AWG, BC Cancer Agency BC, Women’s Hospital BA, Institute B, University B, Reserve University CW, Institute DC, University D, Cancer Centre GP, School HM, Systems Biology IF, KU Leuven KU, Clinic M, Cancer Center MSK, Institute NC, Hospital NC, University S, Alabama UO, Michigan UO, North Carolina UO, Pittsburgh UO, Rochester UO, Southern California UO, Cancer Center UOTMA, Washington UO, Research Institute VA, University V, University W, Broad Institute GSC, St Louis WUI, Cancer Agency GCCB, Institute B, School HM, Hopkins University SKCCCAJ, North Carolina UO, Epigenome Center UOSC, Cancer Center UOTMA, Research Institute VA, Broad Institute GDAC, University: B, School HM, Systems Biology IF, Cancer Center MSK, Santa Cruz UOC, Cancer Center UOTMA, Genomics Consortium BCRI, Children’s Hospital RIAN, Biologic Services TSSA, Center AM, Bioscience A, Hospital BC, BioreclamationIVT, Clinic BM, Medical School CNU, Health System CC, Cureline, University D, University E, University E, of Medicine IUS, of Moldova IOO, Consortium IG, Invidumed, Israelitisches. Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636):169-175, 2017. e-Pub 2017. PMID: 28052061.
122. Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst 4(1):73-83.e10, 2017. e-Pub 2017. PMID: 28017544.
123. Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 12(10):e0186551, 2017. e-Pub 2017. PMID: 29020035.
124. McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol Appl 3:8, 2017. e-Pub 2017. PMID: 28649435.
125. Lisanti S, Garlick DS, Bryant KG, Tavecchio M, Mills GB, Lu Y, Kossenkov AV, Showe LC, Languino LR, Altieri DC. Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. J Biol Chem 291(48):25247-25254, 2016. e-Pub 2016. PMID: 27754870.
126. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834-1856, 2016. e-Pub 2016. PMID: 27043285.
127. Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME. HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. Cancer Res 76(9):2720-30, 2016. e-Pub 2016. PMID: 26984758.
128. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-504, 2016. e-Pub 2016. PMID: 27160903.
129. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, Zorman B, Barzi M, Chen LL, Amin MD, Huang YH, Pautler RG, Hampton OA, Prakash MM, Yang D, Borowiak M, Muzny D, Doddapaneni H, Hu J, Shi Y, Gaber WM, John Hicks M, Thompson PA, Lu Y, Mills GB, Finegold M, Goss JA, Williams Parsons D, Vasudevan SA, Sumazin P, Lopez-Terrada D, Bissig KD. Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Testing of Pediatric Liver Cancer. J Hepatol. e-Pub 2016. PMID: 27117591.
130. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies. Clin Cancer Res 22(7):1592-602, 2016. e-Pub 2016. PMID: 26673799.
131. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14(10):2476-89, 2016. e-Pub 2016. PMID: 26947078.
132. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):801, 2016. e-Pub 2016. PMID: 26865225.
133. and others KD, including Lu Y. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
134. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, [Lu Y] TRN, Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164(3):550-63, 2016. e-Pub 2016. PMID: 26824661.
135. He N, Kim N, Jeong E, Lu Y, Mills GB, Yoon S. Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. Int J Oncol 48(1):67-72, 2016. e-Pub 2016. PMID: 26573869.
136. Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. Sci Rep 6:27391, 2016. e-Pub 2016. PMID: 27272709.
137. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res 6(1):27-37, 2016. e-Pub 2016. PMID: 27073720.
138. Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns WB, Mills GB, Zhao JJ, Baker SJ, Millen KJ. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. Elife 4, 2015. e-Pub 2015. PMID: 26633882.
139. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med, 2015. e-Pub 2015. PMID: 26536169.
140. address: schultz@cbiomskccorg CGARN[YE, Research Network CGA. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163(4):1011-25, 2015. e-Pub 2015. PMID: 26544944.
141. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28(4):529-40, 2015. e-Pub 2015. PMID: 26461095.
142. Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res, 2015. e-Pub 2015. PMID: 26482043.
143. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, [Lu Y] TRN, Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163(2):506-19, 2015. e-Pub 2015. PMID: 26451490.
144. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 28(4):515-28, 2015. e-Pub 2015. PMID: 26439496.
145. Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD, Zhou G, Park YY, Peng G, Gambello MJ, Mills GB. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun 6:7926, 2015. e-Pub 2015. PMID: 26272043.
146. Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene, 2015. e-Pub 2015. PMID: 26212011.
147. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer. Clin Cancer Res, 2015. e-Pub 2015. PMID: 26224872.
148. Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 10(7):e0133219, 2015. e-Pub 2015. PMID: 26181325.
149. [Lu Y] CGAN. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. e-Pub 2015. PMID: 26091043.
150. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Erratum to: Modeling precision treatment of breast cancer. Genome Biol 16:95, 2015. e-Pub 2015. PMID: 25962591.
151. Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R, Consortium (OSBREAC) OBCR, Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med 7(1):21, 2015. e-Pub 2015. PMID: 25873999.
152. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. e-Pub 2015. PMID: 25639871.
153. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 6:4852, 2015. e-Pub 2015. PMID: 25629879.
154. Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res 75(1):203-15, 2015. e-Pub 2015. PMID: 25503560.
155. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6):863-79, 2014. e-Pub 2014. PMID: 25490449.
156. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. e-Pub 2014. PMID: 25380958.
157. Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram PT, Silva JM, Mills GB, Califano A, Sumazin P. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Res. e-Pub 2014. PMID: 25378249.
158. Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB. Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. Cancer Cell 26(4):479-94, 2014. e-Pub 2014. PMID: 25284480.
159. Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 5(19):9049-64, 2014. e-Pub 2014. PMID: 24979294.
160. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26(3):344-57, 2014. e-Pub 2014. PMID: 25203321.
161. [Lu Y] CGARN. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-9, 2014. e-Pub 2014. PMID: 25079317.
162. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, [Lu Y] CGARN, Benz CC, Perou CM, Stuart JM. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 158(4):929-44, 2014. e-Pub 2014. PMID: 25109877.
163. [Lu Y] CGARN. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-50, 2014. e-Pub 2014. PMID: 25079552.
164. Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG. Reverse Phase Protein Array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 20(9):2300-11, 2014. e-Pub 2014. PMID: 24599934.
165. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 111(3):1114-9, 2014. e-Pub 2014. PMID: 24395800.
166. Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. e-Pub 2014. PMID: 24469047.
167. Liu W, Ju Z, Lu Y, Mills GB, Akbani R. A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. Cancer Inform 13:109-17, 2014. e-Pub 2014. PMID: 25374453.
168. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14(1):120, 2014. e-Pub 2014. PMID: 24559118.
169. Yu H, Cai S, Gao J, Zhang S, Lu Y, Qiao X, Yang H, Wang Y. Identification and polymorphism discovery of the cathelicidins, Lf-CATHs in ranid amphibian (Limnonectes fragilis). FEBS J 280(23):6022-32, 2013. e-Pub 2013. PMID: 24028327.
170. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, Wakefield C, Weinstein JN, Mills GB, Liang H. TCPA: a resource for cancer functional proteomics data. Nat Methods 10(11):1046-7, 2013. e-Pub 2013. PMID: 24037243.
171. [Lu Y] CGARN, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113-20, 2013. e-Pub 2013. PMID: 24071849.
172. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, [Lu Y] TRN. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 2013. e-Pub 2013. PMID: 24120142.
173. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Research Network CGA(, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123(9):3740-50, 2013. e-Pub 2013. PMID: 23945238.
174. Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S, Hawke DH, Li J, Dogruluk T, Scott KL, Jonasch E, Mills GB, Ding Z. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. e-Pub 2013. PMID: 23912456.
175. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. e-Pub 2013. PMID: 23851501.
176. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761-9, 2013. e-Pub 2013. PMID: 23619167.
177. [Lu Y] CGARN. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43-9, 2013. e-Pub 2013. PMID: 23792563.
178. [Lu Y] CGARN, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73, 2013. e-Pub 2013. PMID: 23636398.
179. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene. e-Pub 2013. PMID: 23396361.
180. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA. BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal 6(257):ra2, 2013. e-Pub 2013. PMID: 23300339.
181. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. TARDBP regulates glycolysis in hepatocellular carcinomaby regulating PFKP through miR-520. Hepatology, 2013. e-Pub 2013. PMID: 23389994.
182. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biol 14(10):R110, 2013. e-Pub 2013. PMID: 24176112.
183. Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med 13:33, 2013. e-Pub 2013. PMID: 23410205.
184. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18(21):5911-23, 2012. e-Pub 2012. PMID: 22896656.
185. Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics 28(21):2804-10, 2012. e-Pub 2012. PMID: 22923301.
186. Liu Y, Tao X, Jia L, Cheng KW, Lu Y, Yu Y, Feng Y. Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Report 6(5):1006-12, 2012. e-Pub 2012. PMID: 22940905.
187. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 2012. e-Pub 2012. PMID: 23028188.
188. [Lu Y] CGAN. Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70, 2012. e-Pub 2012. PMID: 23000897.
189. Nieto-Barajas LE, Müller P, Ji Y, Lu Y, Mills GB. A time-series DDP for functional proteomics profiles. Biometrics 68(3):859-68, 2012. e-Pub 2012. PMID: 22221181.
190. Oates CJ, Hennessy BT, Lu Y, Mills GB, Mukherjee S. Network Inference Using Steady-State Data and Goldbeter-Koshland Kinetics. Bioinformatics 28(18):2342-8, 2012. e-Pub 2012. PMID: 22815361.
191. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 26(4):1582-92, 2012. e-Pub 2012. PMID: 22198386.
192. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4(1):52-67, 2012. e-Pub 2012. PMID: 22174013.
193. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7(2):e31087, 2012. e-Pub 2012. PMID: 22348039.
194. Claerhout S, Dutta B, Bossuyt W, Zhang F, Nguyen-Charles C, Dennison JB, Yu Q, Yu S, Balázsi G, Lu Y, Mills GB. Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One 7(6):e39400, 2012. e-Pub 2012. PMID: 22745748.
195. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10(1):56, 2012. e-Pub 2012. PMID: 23006314.
196. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8(3):e1002538, 2012. e-Pub 2012. PMID: 22479189.
197. Hoshino D, Jourquin J, Emmons SW, Miller T, Goldgof M, Costello K, Tyson DR, Brown B, Lu Y, Prasad NK, Zhang B, Mills GB, Yarbrough WG, Quaranta V, Seiki M, Weaver AM. Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Sci Signal 5(241):ra66, 2012. e-Pub 2012. PMID: 22969158.
198. Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer, 2012. e-Pub 2012. PMID: 22422301.
199. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. Mol Cancer Ther 10(12):2350-62, 2011. e-Pub 2011. PMID: 21992792.
200. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30(45):4567-77, 2011. e-Pub 2011. PMID: 21666717.
201. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High Frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 1(2):170-85, 2011. e-Pub 2011. PMID: 21984976.
202. Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, Yarden Y. Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Mol Cell 42(4):524-35, 2011. e-Pub 2011. PMID: 21596316.
203. Gupte R, Siddam A, Lu Y, Li W, Fujiwara Y, Panupinthu N, Pham TC, Baker DL, Parrill AL, Gotoh M, Murakami-Murofushi K, Kobayashi S, Mills GB, Tigyi G, Miller DD. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett 20(24):7525-8, 2010. e-Pub 2010. PMID: 21051230.
204. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-151, 2010. e-Pub 2010. PMID: 21691416.
205. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704-14, 2010. e-Pub 2010. PMID: 20643779.
206. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12(6):559-69, 2010. e-Pub 2010. PMID: 20156803.
207. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. e-Pub 2010. PMID: 19435463.
208. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16(10):2852-60, 2010. e-Pub 2010. PMID: 20460476.
209. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, Artavanis-Tsakonas S, Brugge JS. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 107(11):5012-7, 2010. e-Pub 2010. PMID: 20194747.
210. Hong B, Lui VW, Hui EP, Lu Y, Leung HS, Wong EY, Cheng SH, Ng MH, Mills GB, Chan AT. Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 79(6):842-52, 2010. e-Pub 2010. PMID: 19879857.
211. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-54, 2010. e-Pub 2010. PMID: 19730444.
212. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2010. e-Pub 2010. PMID: 20124458.
213. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 5(3):e9910, 2010. e-Pub 2010. PMID: 20361045.
214. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5(7):e11729, 2010. e-Pub 2010. PMID: 20668531.
215. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21-32, 2009. e-Pub 2009. PMID: 19573809.
216. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11):1027-34, 2009. e-Pub 2009. PMID: 19395869.
217. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15(6):539-50, 2009. e-Pub 2009. PMID: 19477432.
218. Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 284(25):16948-55, 2009. e-Pub 2009. PMID: 19414586.
219. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 2009. e-Pub 2009. PMID: 19345329.
220. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4(5):e5583, 2009. e-Pub 2009. PMID: 19440550.
221. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 2008. e-Pub 2008. PMID: 19033662.
222. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100(22):1630-42, 2008. e-Pub 2008. PMID: 19001604.
223. Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 68(8):2895-903, 2008. e-Pub 2008. PMID: 18413758.
224. Ji Y, Lu Y, Mills GB. Bayesian methods based on test statistics for multiple hypothesis testing problems. Bioinformatics 24(7):943-949, 2008. e-Pub 2008. PMID: 18245123.
225. Garlich, JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB. A vascular targeted pan phosphoinositides 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Research 68(1):206-215, 2008. e-Pub 2008. PMID: 18172313.
226. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421-31, 2007. e-Pub 2007. PMID: 18094426.
227. Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich GD. Alkoxymethylenephosphonate analogues of (lyso) phosphatidic acid stimulate signaling networks coupled to the LPA(2) receptor. ChemMedChem 3(2):200, 2007. e-Pub 2007. PMID: 17952880.
228. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39(4):503-12, 2007. e-Pub 2007. PMID: 17322878.
229. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. ACTN4 Regulates AKT1 Function: A Retrovirus-Based Protein Mammalian Complementation Assay Screen Reveals Novel AKT1 Binding Partners. Proc Natl Acad Sci U S A 103(41):15014-19, 2006. e-Pub 2006. PMID: 17018644.
230. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-21, 2006. e-Pub 2006. PMID: 17041095.
231. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66(7):3737-3746, 2006. e-Pub 2006. PMID: 16585200.
232. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3):225-238, 2006. e-Pub 2006. PMID: 16530706.
233. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3):637-644, 2006. e-Pub 2006. PMID: 16546978.
234. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4(11):1681-1686, 2005. e-Pub 2005. PMID: 16275989.
235. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-104, 2005. e-Pub 2005. PMID: 15504738.
236. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-61, 2004. e-Pub 2004. PMID: 14670967.
237. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057-66, 2003. e-Pub 2003. PMID: 12869565.
238. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 2003. e-Pub 2003. PMID: 12714585.
239. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17(4):575-88, 2003. e-Pub 2003. PMID: 12554765.
240. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15):2357-64, 2002. e-Pub 2002. PMID: 11948419.
241. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22(7):2099-110, 2002. e-Pub 2002. PMID: 11884598.
242. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087-92, 2002. e-Pub 2002. PMID: 11861387.
243. Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85(2):303-11, 2001. e-Pub 2001. PMID: 11461094.
244. Mujoo K, Haridas V, Hoffmann JJ, Wachter GA, Hutter LK, Lu Y, Blake ME, Jayatilake GS, Bailey D, Mills GB, Gutterman JU. Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res 61:5486-90, 2001. e-Pub 2001. PMID: 11454696.
245. Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 276:27455-61, 2001. e-Pub 2001. PMID: 11337495.
246. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352(Pt 1):135-43, 2000. e-Pub 2000. PMID: 11062066.
247. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-5, 2000. e-Pub 2000. PMID: 11035810.
248. Mao M, Fang X, Lu Y, Lapushin R, Jr BR, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352(Pt 2):475-82, 2000. e-Pub 2000. PMID: 11085941.
249. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-45, 1999. e-Pub 1999. PMID: 10597304.
250. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5:4308-18, 1999. e-Pub 1999. PMID: 10632375.
251. Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, Mills GB. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 274:27583-9, 1999. e-Pub 1999. PMID: 10488096.
252. Lu Y, Shayesteh L, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102, 1999. e-Pub 1999. PMID: 9916799.
253. Lu Y, Davies MA, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58:5285-90, 1998. e-Pub 1998. PMID: 9850049.
254. Lu Y, Cuevas B, Gibson S, Khan H, LaPushin R, Imboden J, Mills GB. Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J Immunol 161:5404-12, 1998. e-Pub 1998. PMID: 9820515.
255. Gibson S, Truitt K, Lu Y, Lapushin R, Khan H, Imboden JB, Mills GB. Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J 330(Pt 3):1123-8, 1998. e-Pub 1998. PMID: 9494076.
256. Lu Y, Rodriguez R, Bjorndahl J, Phillips CA, Trevillyan JM. CD28-dependent killing by human YT cells requires phosphatidylinositol 3-kinase activation. Eur J Immunol 26:1278-84, 1996. e-Pub 1996. PMID: 8647205.
257. Lu Y, Phillips CA, Trevillyan JM. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity in Jurkat T cells: studies with a selective inhibitor, wortmannin. Eur J Immunol 25:533-7, 1995. e-Pub 1995. PMID: 7875216.
258. Lu Y, Phillips CA, Bjorndahl JM, Trevillyan JM. CD28 signal transduction: tyrosine phosphorylation and receptor association of phosphoinositide-3 kinase correlate with Ca(2+)-independent costimulatory activity. Eur J Immunol 24:2732-9, 1994. e-Pub 1994. PMID: 7957566.
259. Dombrowski KE, Trevillyan JM, Cone JC, Lu Y, Phillips CA. Identification and partial characterization of an ectoATPase expressed by human natural killer cells. Biochemistry 32:6515-22, 1993. e-Pub 1993. PMID: 8329381.
260. Cone JC, Lu Y, Trevillyan JM, Bjorndahl JM, Phillips CA. Association of the p56lck protein tyrosine kinase with the Fc gamma RIIIA/CD16 complex in human natural killer cells. Eur J Immunol 23:2488-97, 1993. e-Pub 1993. PMID: 8405050.
261. Lu Y, Granelli-Piperno A, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28-induced T cell activation. Evidence for a protein-tyrosine kinase signal transduction pathway. J Immunol 149:24-9, 1992. e-Pub 1992. PMID: 1318900.
262. Trevillyan J, Lu Y, Phillips CA. T-lymphocyte activation. Panhandle Health 3:10-11, 1992. e-Pub 1992.
263. Trevillyan JM, Lu YL, Atluru D, Phillips CA, Bjorndahl JM. Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. J Immunol 145:3223-30, 1990. e-Pub 1990. PMID: 2172380.
264. Lu Y, Ma BL, Jin YC. Influence of several factors on human immune response to Trichosanthin. J. Shanghai Immunology 8:166-169, 1988. e-Pub 1988.
265. Lu Y, Ma BL, Jin YC. Significance of several immunologic tests in diagnosis of Trichosanthin induced anaphylaxis. J.Shanghai Immunology 8:86-90, 1988. e-Pub 1988.
266. Lu Y, Wang WC, Xie YL. Detection of human SmIgG on B lymphocytes in peripheral blood with FITC conjugated protein. J. Shanghai Immunology 1:24, 1981. e-Pub 1981.
267. Lu Y, Ma BL. Clinical application of monoclonal antibodies. J. Shanghai Immunology 1:59-62, 1981. e-Pub 1981.

Invited Articles

1. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: Linking Genomics to New Target Discovery and Molecular Markers--The Way Ahead. Adv Exp Med Biol 617(617):23-40, 2008. e-Pub 2008. PMID: 18497028.
2. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. Individualized molecular medicine: Linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 622(622):183-95, 2008. e-Pub 2008. PMID: 18546628.
3. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12)(12):988-1004, 2005. e-Pub 2005. PMID: 16341064.
4. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 403:202-215, 2005. e-Pub 2005. PMID: 16473588.
5. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer. J Cell Biochem 92(6)(6):1115-1140, 2004. e-Pub 2004. PMID: 15258897.
6. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Molecular therapeutics: promise and challenges. Semin Oncol 31(1 Suppl 3):39-53, 2004. e-Pub 2004. PMID: 15052542.
7. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: Targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 2003. e-Pub 2003. PMID: 14613030.
8. Lu Y, Wang H, Mills GB. Targeting PI3K/AKT pathway for cancer therapy. Rev Clin Exp Hematol 7(2):205-228, 2003. e-Pub 2003. PMID: 14763163.
9. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S88-92; discussion S93-6, 2003. e-Pub 2003. PMID: 12586094.
10. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of Lysophospholipids in the Pathophysiology Diagnosis, and Management of Ovarian Cancer. Cancer Treat Res 107:259-83, 2002. e-Pub 2002. PMID: 11775454.
11. Lu Y, Shayestri L, LaPushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Bast RC, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3'kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics. In Ovarian Cancer Oxford University Press:413-422, 2002. e-Pub 2002.
12. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Jaffe R, Gray J, Siminovitch K. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28:125-41, 2001. e-Pub 2001. PMID: 11706404.
13. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98:10031-3, 2001. e-Pub 2001. PMID: 11526226.
14. Mills GB, Lu Y, Shyestri L, Pinkel D, Gray J. From genetics to therapeutic targets: Phosphatidylinositol 3 kinase (PI3K) in ovarian and breast cancer. Cancer: investigatcion basica y aplicaciones clinicas:6-16, 1999. e-Pub 1999.
15. Xu Y, Fang X, Furui T, Sasagawa T, Pustilnik T, Lu Y, Shen Z, Wiener JR, Shayesteh L, Gray JW, Bast Jr RC, Mills GB. Regulation of growth of ovarian cancer cells by phospholipid growth factors. Ovarian Cancer 5:109-120, 1998. e-Pub 1998.

Review Articles

1. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol 43(4):476-83, 2016. e-Pub 2016. PMID: 27663479.
2. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4(4):346-55, 2005. e-Pub 2005. PMID: 15671044.

Abstracts

1. Lu Y, Morgan-Lappe S, Yu Q, Yu S, Luo Y, Liu W, Joy C, Fesik S, Mills GB. Identify on and off target effects of targeted therapeutics on signaling networks by RPPA. Proceedings of AACR Annual Meeting 48, 2007. e-Pub 2007.
2. Lu Y, Hennessy B, Siwak D, Tibes R, Yu Q, Yu S, Mills GB. Reverse phase protein microarrays is sensitive, stable and quantitative in clinical application. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, 2006. e-Pub 2006.
3. Lu Y, Su JD, Yu Q, Yu S, Rovori M, Kundra V, Miller T, Patterson M, Garlich J, Mills GB. Identification of molecular markers for selection of patients likely to respond and parmacodynamic markers of delivery of biologically relevant dose and early response to a novel phosphatidylinositol 3-kinase (PI3K) inhibitory prodrug, SF1126. Proceedings of the 9th Annual Meeting of the American Association for Cancer Research, 2006. e-Pub 2006.
4. Lu Y, Ruan M, Mills G. Sensitivity and Stability studies for the reverse phase protein microarray technology applied in clinical diagnosis. Proceedings of the CHI Conference on Proteomics, 2005. e-Pub 2005.
5. Lu Y, Yu QH, Hassan H, Yu S, LaPushin R, Mills GB. Tissue lysate arrays as a cell-based assay for molecular screening of AKT inhibitors. Proceedings of the 16th EORTC-NCI AACR Symposium on Molecular Targeted Cancer Therapeutics, 2004. e-Pub 2004.
6. Lu Y, Yu QH, Hall H, Mills GB. Inhibition of PI3K-AKT pathway as a therapeutic target for breast cancer. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research, 2003. e-Pub 2003.
7. Lu Y, Liu JH, Zhang JY, Wang H, Koul D, McMurray JS, Fang XJ, Yung WA, Simnovitch KA, Mills GB. Involvement of the Src family protein tyrosine kinases and the SHP-1 tyrosine phosphatase in the phosphotyrosine-dependent regulation of the PTEN activity. Proceeding of the 93rd Annual Meeting of the American Association for Cancer Research, 2002. e-Pub 2002.
8. Lu Y, Cuevas B, Lin YZ, Koul D, Steck PA, Siminovitch K, Mills GB. Functional Interaction of the SHP1 SH2 Domain containing tyrosine phosphatase with the PTEN tumor suppressor gene is regulated by growth factors. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, 2000. e-Pub 2000.
9. Lu Y, Lin YZ, LaPushin R, Fang X, Yu S, Davies MA, Khan H, Cuevas B, Furui T, Mao M, Zinner R, Hung MC, Steck PA, Mills GB. The MMAC1/PTEN tumor suppressor gene negatively regulates P13K-dependent signaling in breast cancer cells. Proceedings of the the AACR Annual Meeting, Philadelphia 40:685, 1999. e-Pub 1999.
10. Shayesteh L, Lu Y, Kuo WL, Collins C, Pinkel D, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research, New Orleans 39:471, 1998. e-Pub 1998.
11. Wu JY, Xu FJ, Yu YH, Lu Y, Bast RC. Differential signaling induced by heregulin and antibodies to p185c-erbB-2 (p185HER-2) in SKBr3 breast cancer cells that overexpress the receptor. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 39:471, 1998. e-Pub 1998.
12. Lu Y, Wu JY, LaPushin R, Mills GB, Xu FJ, Bast RC, Yu YH. Ras-related NOE Y2 is a novel negative regulator of T cell signaling. Proceeding of the 89th Annual Meeting of the American Association for Cancer Research 39:534, 1998. e-Pub 1998.
13. Lu Y, Gibson S, Khan H, Cuevas B, LaPushin R, Mills GB. ITK/EMT forms a tertiary complex with PI3K and CD28. Proceedings of the 88th Annual Meeting of the American Association for Cancer Research 38:64, 1997. e-Pub 1997.
14. Lu Y, Trevillyan JM, Bjorndahl JM, Phillips CA. Phorbol ester treatment increases IL-2 production but decreases CD28-dependent cellular cytotoxicity. The FASEB Journal 10:A1450, 1996. e-Pub 1996.
15. Trevillyan JM, Lu Y, Rodriguez RR, Phillips CA. Phosphatidylinositol 3-kinase activity is required for CD28-dependent cellular cytotoxicity. Proceedings of the 9th International Congress of Immunology, 1995. e-Pub 1995.
16. Trevillyan JM, Lu Y, Phillips CA. Phosphatidylinositol 3-kinase activity is not essential for CD28 costimulatory activity: Studies with a selective inhibitor, wortmannin. J Leukocyte Biology, Supplement:Abst LB45, 1994. e-Pub 1994.
17. Lu Y, Bjorndahl JM, Phillips CA, Trevillyan JM. Oligomerization of the CD28 receptor on human T-lymphocytes induces the association and tyrosyl phosphorylation of phosphatidylinositol 3-kinase. The FASEB Journal 8:A781, 1994. e-Pub 1994.
18. Lu Y, Rodriguez RR, Bjorndahl JM, Trevillyan JM, Phillips CA. Phosphatidylinositol 3-kinase activity is essential for human natural killer (NK) cell antibody-dependent cellular cytotoxicity (ADCC). J. Leukocyte Biology, Supplement:Abst 8, 1994. e-Pub 1994.
19. Lu Y, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28-induced early signal transduction events require p56lck. J. Immunology 150:186A, 1993. e-Pub 1993.
20. Dombrowski KE, Trevillyan JM, Cone JC, Lu Y, Phillips CA. Identification of an EctoATPase expressed by the human natural killer cell line NK3.3.: Possible role in cell mediated cytotoxicity. J. Immunology 150:208A, 1993. e-Pub 1993.
21. Bjorndahl JM, Lu Y, Trevillyan JM. Activation of a protein-tyrosine kinase pathway is required for CD69 signal transduction. J. Immunology 150:186A, 1993. e-Pub 1993.
22. Lu Y, Ganelli-Piperno A, Bjorndahl JM, Phillips CA, Trevillyan JM. CD28 induced T-cell activation: Evidence for a protein-tyrosine kinase signal transduction pathway. The FASEB Journal 6(4):1224, 1992. e-Pub 1992.
23. Trevillyan JM, Lu Y, Phillips CA. CA T-lymphocyte activation. Panhandle Health 3:10-11, 1992. e-Pub 1992.
24. Cone JC, Lu Y, Bjorndahl JM, Nuwayhid N, Trevillyan JM, Phillips CA. Signal transduction requirement of the Fc RIII/CD16 in the continuous NK cell line, NK3.3. Proceedings of the 8th International Natural Killer Cell Workshop and the 1st Meeting of the Society for Natural Immunity: Molecular and Cellular Aspects of Natural Killer Cell Triggering and Signaling, 1992. e-Pub 1992.
25. Bjorndahl JM, Lu Y, Trevillyan JM. Signal transduction via CD69 requires the activation of a PTK pathway. Proceedings of the Texas Immunology Conference, 1992. e-Pub 1992.
26. Cone JC, Lu Y, Trevillyan JM, Phillips CA. FcyRIII and protein tyrosine kinase signal transduction in a continuous human NK cell line. Proceedings of the 28th National Meeting of the Society for Leukocyte Biology, 1991. e-Pub 1991.
27. Courtney A, Wright SE, Lu Y, Trevillyan JM. Insect cell expression of lymphocyte protein-tyrosine kinase (p56lck) using baculovirus vector. Proceedings of the 67th Annual Meeting of the American Association for the Advancement of Science, Southwestern and Rocky Mountain Division, 1991. e-Pub 1991.
28. Trevillyan JM, Lu Y, Bjorndahl JM, Phillips CA. T-cell activation via CD28 pathway is blocked by a selective protein-tyrosine kinase inhibitor. The FASEB Journal 4(7):P.A2200, 1990. e-Pub 1990.
29. Trevillyan JM, Bjorndahl JM, Lu Y, Atluru R. Inhibition of T-lymphocyte activation by a selective inhibitor of protein-tyrosine kinase. Blood 74:225a, 1989. e-Pub 1989.
30. Lu Y, Ma A. Separation and identification of T and B lymphocytes from murine spleen. Selection of Abstracts 1979-1982, 1982. Shanghai Institute of Immunology:35, 1982. e-Pub 1982.

Book Chapters

1. Siwak DR, Li J, Akbani R, Liang H, Lu Y. Analytical Platforms 3: Processing Samples via the RPPA Pipeline to Generate Large-Scale Data for Clinical Studies. In: Advances in Experimental Medicine and Biology/Springer, 113-147, 2019.
2. Smith DL, Nolden LK, Mills GB, Lu Y. Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling. (Invited). In: Cancer Drug Discovery and Development Apoptosis, Senescence and Cancer. The Human Press, 313-334, 2007.
3. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Nolden L, Hortobagyi G, Mills GB. Targeted Therapeutics in Breast Cancer: Challenges to Success. In: Diseases of The Breast. 3rd. Lippincott Williams and Wilkins, 397-413, 2004.
4. Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Bast RC, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3 kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics. In: Ovarian Cancer, 413-422, 2002.
5. Gray JW, Collins C, Pinkel D, Shayesteh L, Lu Y, Mills GB. Genome scanning and gene discovery in breast and ovarian cancer. In: Proceedings of the 9th Pezcoller Foundation Symposium on the Biology of Tumors, 65-72, 1998.

Patents

1. Genetic Alterations Associated with Cancer (MDA 98-027CIP1). Patent Number: T0207O-067720US.